Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

HKG: 6887

    • Home
    • HKG: 6887
Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) and Xtalpi Inc. (HKG: 2228) announced plans to...

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Fineline Cube Jan 15, 2026

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced the launch of an AI-powered R&D platform focused...

Company Deals

Sunshine Lake Pharma Lists on HKEX via Introduction Method

Fineline Cube Jun 30, 2025

China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...

Recent updates

  • Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China
  • Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada
  • Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer
  • WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects
  • Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Company Drug

Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada

Company Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Company

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.